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as well as female gender revealed significant effects in mod-
el fit indices, which remained stable at 6- and 12-month fol-
low-up examinations. The pre-post effect was pronounced 
for patients with clinically relevant depressive symptoms at 
baseline.  Conclusions: LCSM confirmed the antidepressant 
effect of the CORDIAL therapy program, which was limited 
to women. The effect was pronounced in patients with clini-
cally relevant depressive symptoms at baseline. Method-
ologically, LCSM appears well suited to analyzing longitudi-
nal data from clinical trials in aged populations, by account-
ing for the high between-subject variability and providing 
information on the differential indication of the probed in-
tervention.  © 2015 S. Karger AG, Basel 
 Introduction 
 The worldwide rise in life expectancy will exert an ef-
fect on research in psychotherapy  [1] . There is an urgent 
need to evaluate existing interventions for the elderly and 
to develop or adapt interventions for patients with age-
associated disorders  [2] . However, research in this field 
faces major methodological challenges. As a well-estab-
lished finding in lifespan research, between-subject vari-
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 Abstract 
 Background: Developing and evaluating interventions for 
patients with age-associated disorders is a rising field in psy-
chotherapy research. Its methodological challenges include 
the high between-subject variability and the wealth of influ-
encing factors associated with longer lifetime. Latent change 
score modeling (LCSM), a technique based on structural 
equation modeling, may be well suited to analyzing longitu-
dinal data sets obtained in clinical trials. Here, we used LCSM 
to evaluate the antidepressant effect of a combined cogni-
tive behavioral/cognitive rehabilitation (CB/CR) intervention 
in Alzheimer’s disease (AD).  Methods: LCSM was applied to 
predict the change in depressive symptoms from baseline as 
an outcome of the CORDIAL study, a randomized controlled 
trial involving 201 patients with mild AD. The participants 
underwent either the CORDIAL CB/CR program or standard 
treatment. Using LCSM, the model best predicting changes 
in Geriatric Depression Scale scores was determined based 
on this data set.  Results: The best fit was achieved by a mod-
el predicting a decline in depressive symptoms between be-
fore and after testing. Assignment to the intervention group 
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ability increases with age  [3] . Especially above the age of 
70 years, the range of diversity in cognitive and somatic 
functioning, as well as in quality of life, is broader than in 
earlier life periods  [4] .
 As a consequence of age-associated diversity, the im-
pact of factors which influence the outcome of psycho-
therapy rises with age. Conventional statistical approach-
es such as general linear model (GLM)-based data analy-
ses – for instance, t testing, ANOVAs, and ANCOVAs 
using pre-post differences in outcome measures between 
intervention and control groups – come along with a 
number of strong assumptions. Most importantly for 
clinical research, the assumption of normally distributed 
variables is likely to be violated when using clinical sam-
ples. Whereas such violations can be regarded as less crit-
ical  [5] , they become increasingly problematic if group 
variances are heterogeneous  [6] . Even though remedies 
such as the Welch or Brown-Forsythe test have been in-
troduced  [7] , it remains problematic that all of these ap-
proaches rely on approximating minimal variance within 
groups, which might, in older samples, imply a bias to-
wards underestimating treatment effects.
 ANCOVAs, which are often recommended as the 
method of choice when comparing two groups in a pre-
post design  [8] , have been shown to result in disrupted 
significance levels if unequal regression slopes and un-
equal group sizes go along with nonnormality. Thus, in 
the case of clinical studies where the influence of the pre-
condition on the postcondition is not equal across groups, 
ANCOVA results might be problematic. Recent clinical 
studies often use more than two measurement points, 
which further lowers the usability of ANCOVAs. This 
leaves repeated-measures ANOVA as another method of 
choice. However, it has been shown that violations due to 
group effects (e.g., patients all being in the same clinic) 
can substantially influence the results  [9] . A further criti-
cal issue leading to false-positive results in repeated-mea-
sures ANOVAs is the violation of the sphericity assump-
tion  [10] . Sphericity means that the variance of all pair-
wise differences between measures is constant. This 
assumption is very likely to be violated if therapy effects 
are not uniform. Thus, common approaches to testing 
therapy effects across time are problematic for several 
reasons. 
 In addition to the likelihood of incorrectly estimating 
the significance of treatment effects, the GLM-based ra-
tionale bears the risk of limiting our knowledge regarding 
differential indication in clinical studies  [11] . It leaves 
open the clinician’s most relevant question in view of 
short-running health care resources, that is, whether psy-
chotherapy will be more or less effective for an older pa-
tient with specific demographic or medical characteris-
tics. In other words, GLM-based approaches are restrict-
ed by the way differential therapy outcomes can be 
explored.
 Latent change score modeling (LCSM)  [12, 13] , a 
structural equation modeling-based technique, may rep-
resent an alternative approach. Structural equation mod-
eling-based analyses have been widely used in large lon-
gitudinal studies and aging research within the previous 
decade  [14–16] . While this method has proven to be use-
ful in epidemiological studies involving neurological pa-
tients  [17] , it is rarely applied in clinical trials. However, 
LCSM might be especially well suited to this purpose as it 
permits the identification of relationships between base-
line levels and changes in individual trajectories. It also 
allows the researcher to determine the influence of prese-
lected factors on change in the outcome score. Moreover, 
LCSM makes it possible to examine changes that follow 
upon each other. Finally, it is well suited to detecting 
complex patterns of covariances in larger sets of continu-
ous variables. Moreover, modern statistical packages pro-
vide a number of different robust estimators dealing with 
nonnormality or ordinal data. Thus, in contrast to tradi-
tional GLM-based methods, LCSM not only is more ro-
bust but even relies on broad between-subject variability, 
a core feature of data obtained from the aged.
 In the present study, LCSM was applied to data ob-
tained from the CORDIAL study  [18] , a clinical trial in-
vestigating the effectiveness of a multicomponent inter-
vention combining cognitive behavioral (CB) and cogni-
tive rehabilitation (CR) approaches to Alzheimer’s disease 
(AD). The intervention consisted of 12 weekly individual 
1-hour sessions, organized in 4 thematic modules, flanked 
by an introductory and a closing module. The thematic 
therapy modules focused on using compensatory memo-
ry aids (module 2), establishing daily routines (module 3), 
enhancing pleasant activities (module 4), and self-sup-
porting reminiscence (module 5). The study involved 201 
patients from 5 outpatient units at university clinics and 
from 5 neuropsychiatric practices. All centers strictly fol-
lowed the same protocol and adhered to the same criteria 
for subject enrolment and assessment as well as adminis-
tration of interventions. Participants were assessed at 
baseline and after the intervention (at 0 and 3 months) as 
well as in 2 follow-ups 6 and 12 months thereafter. The 
primary outcome measure was the change in functional 
ability from baseline to after testing as measured by the 
Bayer Activities of Daily Living (B-ADL) scale. Secondary 
outcome measures were a change as described above in 
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Dementia Quality of Life scale (DEMQOL), Neuropsy-
chiatric Inventory (NPI), a cognitive test battery, a patient 
satisfaction scale (ZUF-8), and the Geriatric Depression 
Scale (GDS). Further details of this study, not yet involv-
ing the 12-month follow-up, have been reported in the 
original paper  [18] . Of importance for the present study, 
GLM-based comparisons of the intervention and control 
groups indicated that after the test and at the 6-month 
follow-up, depressive symptoms were significantly re-
duced in women but not in the total sample. Otherwise, 
there were no significant changes in the outcome mea-
sures. 
 Our current re-analysis of the data was motivated by 
two aspects of the study. First, as in most studies on psy-
chosocial interventions in AD, the patient sample was not 
stratified for gender. The gender ratio was 1: 1 instead of 
1: 2, which would correspond to the higher prevalence of 
AD in elderly women  [19, 20] . Second, the degree of de-
pressiveness as measured by the GDS at baseline greatly 
varied between 0 and 28 symptoms reported. For the rea-
sons explained above, these two aspects gave rise to the 
hypothesis that the antidepressant effect of the interven-
tion might have been underestimated by the GLM-based 
methodology. In the present study, we therefore re-ana-
lyzed the data of the CORDIAL study in order to examine 
the combined effects of group assignment and gender on 
depressiveness in early AD. An optimal model fit was in-
tended for the total sample, and additionally for the sub-
sample with clinically relevant depressive symptoms. 
 Subjects and Methods 
 Participants 
 All participants were community-dwelling patients diagnosed 
with mild dementia in AD (ICD-10 research criteria, MMSE score 
>20) at an average age of 73.7 years (SD = 7.9) who did not have 
any other psychiatric or physical disorders. They were randomly 
assigned to either an intervention group (IG) or a control group 
(CG) and assessed 4 times by blinded, trained raters: at baseline 
before the intervention (t 0 ) and approximately 3 months later di-
rectly after the intervention (t 1 ) as well as at 2 follow-ups (t 2 and 
t 3 ) 6 and 12 months after the intervention. The CG was slight-
ly older (mean = 75.1 years, SD = 7.1, p = 0.016) than the IG
(mean = 72.4 years, SD = 8.5). The dropout rates were very favor-
able compared to clinical studies in general and those in AD spe-
cifically: 8 and 4% at t 1 , 17 and 12% at t 2 , and 24 and 21% at t 3 for 
the IG and the CG, respectively. Dropout at t 1 depended on an 
interaction of center, gender, and group (F = 2.60, df = 9, p < 0.01); 
subsequent dropout was not associated with these variables. Drop-
out associated with center, gender, and group was handled in the 
main analyses. A detailed description of the intervention, partici-
pant characteristics, and study design is given in Kurz et al.  [18] .
 Assessment of Depressive Symptoms 
 The primary outcome for the present analyses was the GDS 
 [21] , German version  [22] , a 30-item self-report measure to be 
confirmed or rejected by the patient, yielding sum scores between 
0 and 30. Scores of  ≥ 10 are considered clinically relevant signs of 
depression  [23, 24] ; they were therefore selected as a criterion for 
depression as part of the BPSD (behavioral and psychological 
symptoms of dementia) syndrome in AD.
 Statistical Analyses 
 Analyses were based on the data on the intention-to-treat pop-
ulation. LCSM was applied  [13] using Mplus version 5.2  [25] . In 
order to systematically test alternative assumptions, nested mul-
tiple group models ( fig. 1 ) were compared. Aiming for a parsimo-
nious yet well-fitting model, we systematically introduced con-
straints to the model just identified and tested for a resulting loss 
of model fit. One by one, we constrained each parameter to 0, and 
if that led to worse fit, we constrained it to be of the same value 
across groups. If this led to worse fit, we concluded there must be 
group differences in this parameter and allowed the model to esti-
mate them  [17, 26] . This way, we kept each parameter that, if con-
strained, resulted in a loss of model fit.
 Loss of model fit was defined as a significant difference in like-
lihood as tested by the χ 2 statistic (α level: p = 0.05). As this test 
might be underpowered with small samples, we supplemented it 
with the comparative fit index (CFI), the root mean square error 
of approximation (RMSEA), and the standardized root mean 
square residual (SRMR). Whenever the χ 2 difference test indicated 
a significant worsening of model fit after adding a constraint to the 
model, we refrained from that constraint. When it was nonsignif-
icant, we inspected the other fit indices mentioned above and re-
frained from a constraint whenever we simultaneously observed a 
decrement of >0.005 in the CFI, a change of >0.010 in the RMSEA, 
and a change of >0.025 in the SRMR (for intercepts, a change 
>0.005). Simulations have demonstrated that these cutoffs are sen-
sitive to test measurement invariance across groups  [27] . Thus, we 
iteratively tested whether constraining parameters led to a de-
crease in model fit to explore group differences. By doing so, we 
explicitly examined possible group differences in all modeled pa-
rameters. Finally, we combined all possible constraints in a parsi-
monious model. This final model then assumedly contained all 
parameters necessary to model group differences in the data. In a 
next step, we evaluated the estimated values for each parameter to 
assess the strengths of the associations or differences as well as 
their statistical significance. We achieved this by again constrain-
ing one parameter after the other to 0 or, if constraint to 0 was 
impossible, to an equal value across groups. The p value from the 
χ 2 difference test indicated the statistical significance of a param-
eter estimate.
 The models were estimated using a robust estimator (MLR) 
implemented in Mplus 7  [25] . χ 2 difference tests were corrected 
with the scaled formula by Satorra and Bentler  [28] . All the esti-
mated models included ‘study center’ as a cluster variable to ac-
count for clustered sampling.
 Missing data due to dropout were dealt with by full information 
maximum likelihood estimation  [29] . The main advantage of this 
algorithm is that it takes into account all information available 
from the variables included in the model when estimating param-
eters; that is, even cases with partly missing data are included with-
out former imputation of the missing values. This was shown to 
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yield less bias in the estimated population parameters than other 
widely used methods  [30] .
 The respective influence of gender on the change scores was 
measured by testing the increment in explained variance when in-
cluding gender into the model. Observed GDS scores were cen-
tered on the group-specific average score at t 0 , so that the inter-
cepts of the change scores represent change in depressive symp-
toms for a person from the average score of the respective group. 
Gender was coded binarily (men = 0, women = 1), so that the mean 
difference between average male and female patients is estimated 
by the path coefficient gender – latent change score. The intercepts 
of the change scores represent change for an average male patient 
of the respective group, whereas the path coefficient gender – la-
tent change score adds to the intercept to depict change for an av-
erage female patient (see  fig. 1 ).
 For all t tests or ANOVAs, homogeneity of variances was tested 
with Levene’s test, and, if significant, corrected values are reported. 
For ANOVAs, Bonferroni-corrected values are reported when ap-
propriate. t tests and ANOVAs were conducted with SPSS 19 
(IBM), and effect sizes were calculated using G * Power  [31] . Sig-
nificance was tested using a 5% α level (two-tailed).
 Results 
 Model Fit for the Total Sample 
 At baseline, the number of depressive symptoms did 
neither differ between men and women (p = 0.96) nor 
ı ı ı
ı ı ı
Dept0 Dept1 Dept2 Dept3
©Dept1t0 ©Dept2t1 ©Dept3t2
Gender
Before Intervention After Intervention 6-month follow-up 12-month follow-up
–0.83 –0.13 1.09
–0.33***
IG: –5.39*
CG: –5.02*
IG: 0.74
CG: 0.35
IG: –1.53**
CG: –0.28
IG: 11.01
CG: 14.1
IG: 0.02
CG: 0.05
IG: 13.39
CG: 9.02
IG: 18.81
CG: 23.35
–0.46* –0.67*
–0.08
 Fig. 1. Preferred model, unstandardized path coefficients, inter-
cepts and covariances for the CG and the IG, respectively. Inter-
cepts (in bold type) of the change scores (ΔDep) represent change 
in depressive symptoms for a person with the average score of the 
respective group. Gender was coded binarily (men = 0, women = 
1), so that the intercepts of the change scores represent change for 
an average male patient of the respective group, whereas the path 
coefficient gender – latent change score (in italics) adds to the in-
tercept to depict change for an average female patient. When just 
one coefficient is depicted, it is set equal in both groups. If no coef-
ficients are depicted, the path is fixed to 1. Plain: residual variance; 
bold type: intercepts; italics: path coefficients, covariances. 
 * / * * / * * *  Significance according to the χ 2 difference test, testing this 
model against one in which the respective parameter is fixed. Re-
sidual variances were not tested. Fit indices: χ 2 value (df = 11) = 
9.74; RMSEA = 0 (90% CI: 0–0.095); CFI = 1; SRMR = 0.062. ε = 
latent variable. 
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between groups (p = 0.33). The most parsimonious mod-
el, henceforth defined as the preferred model ( fig.  1 ), 
showed a good model fit [χ 2 value (df = 11) = 9.74;
RMSEA = 0 (90% CI: 0–0.095); CFI = 1; SRMR = 0.062]. 
After being pruned in the way described, the preferred 
model estimated GDS change over time, GDS baseline ef-
fects on GDS change, and gender effects on GDS change. 
Importantly, group differences were estimated in the ef-
fect of gender (group by gender interaction) on GDS 
change during the intervention (ΔDep t 1 t 0 ) and during the 
first follow-up period (ΔDep t 2 t 1 ). The preferred model in-
cluded the following constraints: (a) to be 0, the influence 
of baseline GDS score and of gender on GDS score change 
in the second follow-up period (ΔDep t 3 t 2 ), and (b) to be 
equal across groups, the influence of baseline GDS score 
on ΔDep t 1 t 0 and ΔDep t 2 t 1 as well as the intercepts of all 
ΔDep scores ( fig. 1 ). 
 According to the preferred model, an averagely de-
pressed male patient would show a nonsignificant de-
crease in symptoms by 0.83 GDS points (β 0 = –0.83;
Δχ 2 S-B-scaled = 2.03, Δdf = 1, p Δχ 2 = 0.154) during the inter-
vention period irrespective of group assignment. In con-
trast, for female patients, the extent of decrease depended 
on group assignment ( fig. 2 ). This was evident in a sig-
nificant path coefficient from gender to ΔDep t 1 t 0 in the IG 
(β unstd = –1.52; Δχ 2 S-B-scaled = 6.47, Δdf = 1, p (Δχ 2 ) = 0.011) 
but not in the CG (β unstd = 0.28, Δχ 2 S-B-scaled = 0.28, Δdf = 
1, p Δχ 2 = 0.60), meaning that being a female patient re-
sulted in a 1.52 times higher GDS score after the interven-
tion as compared to being a male patient. The difference 
between the groups in the gender effect was significant 
(Δχ 2 S-B-scaled = 8.53, Δdf = 1, p Δχ 2 = 0.003), indicating a 
group by gender interaction. 
 As a further result of the preferred model, in both 
groups, the number of symptoms at baseline affected the 
first change score (β unstd = –0.33; Δχ 2 S-B-scaled = 94.21,
Δdf = 1, p Δχ 2 < 0.001); that is, 1 point higher on the GDS 
at baseline went along with a decrease of 0.33 GDS points 
during the intervention, in addition to the –0.83-point 
change intercept for male patients and the –0.83-point 
change intercept plus –1.52-point gender effect for fe-
male patients. In the CG, the model explained 17.9% of 
the total variance of the first change score; a model with-
out gender explained 17.5%. In the IG, the model ex-
plained 22% of the total variance; a model without gender 
explained 17.6%. Both overall effect sizes can be consid-
ered as moderate to large  [32] .
 Regarding the follow-up periods, the only significant 
group difference was to be found in the effect of gender 
on ΔDep t 2 t 1 , that is, the first follow-up period. In the CG, 
women showed slightly less of a decrease in depressive 
symptoms than men, as indicated by a nonsignificant-
ly positive effect of gender on ΔDep t 2 t 1 (β unstd = 0.35;
Δχ 2 S-B-scaled = 0.26, Δdf = 1, p Δχ 2 = 0.61). In the IG, women 
showed slightly more of a decrease in depressive symp-
toms than men, as indicated by a nonsignificantly positive 
effect of gender on ΔDep t 2 t 1 (β unstd = –0.74; Δχ 2 S-B-scaled = 
0.97, Δdf = 1, p Δχ 2 = 0.33). Group differences in gender 
effects (group × gender interaction) were also nonsignif-
icant (Δχ 2 S-B-scaled = 1.1, Δdf = 1, p Δχ 2 = 0.29). The intercept 
of ΔDep t 2 t 1 was nonsignificant in either group, indicating 
no further mean change for men irrespective of group 
(β 0 = –0.13; Δχ 2 S-B-scaled = 0.11, Δdf = 1, p Δχ 2 = 0.74). The 
preferred model explained 26.6% of the total variance in 
ΔDep t 2 t 1 (without gender: 25%) in the CG. In the IG, the 
model explained 15.2% of the variance in ΔDep t 2 t 1 (with-
out gender: 14.7%). Both overall effects can be regarded 
as moderate to large  [32] . ΔDep t 3 t 2 had a positive intercept 
(β 0 = 1.1; Δχ 2 S-B-scaled = 3.46, Δdf = 1, p Δχ 2 = 0.06); it was 
set to be equal across groups and genders, indicating a 
mean increase in depressive symptoms across groups and 
genders between 6 and 12 months after the intervention. 
In the CG, the model explained 9.3% of the variance in 
ΔDep t 3 t 2 (without gender: 9.4%), and in the IG, it ex-
plained 16.9% of the variance (without gender: 16.5%), 
–8.00
–7.00
–6.00
–5.00
–4.00
–3.00
–2.00
–1.00
0
1.00
2.00 All
Male
GDS score >9
Female
CG IG
Male Female
 Fig. 2. Mean change in depressive symptoms during the interven-
tion as predicted by the preferred model, according to gender and 
group. Error bars: 95% CIs. Note that the depicted means of the 
latent change factor scores can be directly interpreted for prognos-
tic use. For example, the model predicts that the GDS score of a 
female patient ranging above cutoff at baseline would drop by 5.53 
points if the intervention were applied, but only by 1.81 points if 
the intervention were not applied. 
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indicating that previous GDS, but not gender, had a mod-
erate effect on follow-up GDS change in both groups.
 Our fourth step of analysis addressed the within-per-
son stability of the GDS scores in the follow-up periods. 
Each Δ negatively influenced the next Δ ( fig. 1 ), indicat-
ing fluctuations such as that high scores tended to drop 
more and vice versa. There were no significant group dif-
ferences in these parameters, meaning that these fluctua-
tions were similar in both groups.
 Model Fit for Clinically Depressed Patients 
 A similar model, but reduced to 3 measurement occa-
sions, was tested in a subsample of clinically depressed 
patients, defined by a GDS score of  ≥ 10  [23] . At t 0 , the 
depressive subsample differed from the nondepressive 
counterpart with respect to GDS score (mean = 14.2 vs. 
5.5; t df = 199 = –20.67, p < 0.001, power = 1; effect size d = 
2.8) but not to age (mean = 73.8 vs. 73.7 years; t df = 199 = 
0.015, p = 0.99, power = 0.05; effect size d = 0.002) or 
years of education (mean = 12.3 vs. 12.7 years; t df = 199 = 
0.95, p = 0.34, power = 0.12; effect size d = 0.11). Impor-
tantly, being in the subsample was neither affected by 
group assignment nor by gender (ANOVAs: p > 0.71). 
Within the subsample, GDS scores at t 0 did not differ be-
tween men and women [difference between means (dif-
f M-M ) = 0.23, t df = 77 = 0.29, p = 0.77, power = 0.06; ef-
fect size d = 0.07] or between groups (diff M-M = 0.79,
t df = 77 = 1.02, p = 0.31, power = 0.17; effect size d = 0.23). 
Due to the small sample size of the subsamples (CG: n = 
41; IG: n = 38), reliable testing was only possible for a 
model with 3 time points.
 The preferred model allowed for the following con-
straints. The ensuing parameters could be set equal across 
groups: intercepts of both ΔDep t 1 t 0 and ΔDep t 2 t 1 (GDS 
change in men), influence of baseline GDS score on 
ΔDep t 1 t 0 , and influence of ΔDep t 1 t 0 on ΔDep t 2 t 1 . Effects of 
gender on ΔDep t 2 t 1 could be set to 0. The preferred mod-
el fit the data well [χ 2 value (df = 6) = 2.13; RMSEA = 0 
(90% CI: 0–0.116); SRMR = 0.04]. 
 Following the preferred model, the pattern of results 
largely resembled that of the model for the full sample. A 
male participant of either group with a mean GDS score 
(group mean) at baseline would experience a drop in GDS 
score by –1.52 points during the intervention (β 0 = –1.52; 
Δχ 2 S-B-scaled = 3.21, Δdf = 1, p Δχ 2 = 0.07) and by –0.49 dur-
ing the first follow-up period (β 0 = –0.49; Δχ 2 S-B-scaled = 
0.57, Δdf = 1, p Δχ 2 = 0.55); both reductions were not sig-
nificant. As in the total sample, there was a significant 
group difference in the effect of gender on change during 
the intervention (Δχ 2 S-B-scaled = 6.54, Δdf = 1, p Δχ 2 = 0.01). 
More specifically, a significant effect of gender on ΔDep t 1 t 0 
was present in the IG (β unstd = 3.92; Δχ 2 S-B-scaled = 14.79, 
Δdf = 1, p Δχ 2 < 0.001; being a woman meant a reduction 
of –3.92 GDS points more compared to being a man) but 
not in the CG (β unstd = –0.62; Δχ 2 S-B-scaled = 0.23, Δdf =
1, p Δχ 2 = 0.63). Together, this indicates the same treat-
ment × gender interaction effect as in the total sample, 
such that gender differences in the reduction of depres-
sive symptoms during the intervention were only present 
in the IG and intervention effects were only present for 
female patients.
 As shown in  figure 2 , these effects were more pro-
nounced in the depressed subgroup than in the total
sample. As in the total sample, baseline GDS score influ-
enced ΔDep t 1 t 0 similarly in both groups (β unstd = –0.31; 
Δχ 2 S-B-scaled = 5.99, Δdf = 1, p Δχ 2 = 0.014; the higher the 
baseline GDS score, the higher the reduction during the 
intervention). Concerning the follow-up period, ΔDep t 1 t 0 
influenced ΔDep t 2 t 1 , indicating fluctuations in the GDS 
score (β unstd = –0.45; Δχ 2 S-B-scaled = 8.57, Δdf = 1, p Δχ 2 = 
0.003; the higher the GDS score after the intervention, the 
lower it was after follow-up). Importantly, as in the total 
sample, these values did not differ between groups. In 
contrast to the results from the total sample, the baseline 
GDS score influenced also ΔDep t 2 t 1 in the IG (β unstd = 
–0.54; Δχ 2 S-B-scaled = 7.37, Δdf = 1, p Δχ 2 = 0.007; the higher 
one started, the more reduced a score one had in the fol-
low-up period), but it did not so in the CG (β unstd = –0.08; 
Δχ 2 S-B-scaled = 0.27, Δdf = 1, p Δχ 2 = 0.60). 
 In the CG, the preferred model explained 6.8% of the 
total variance of ΔDep t 1 t 0 ; a model without gender ex-
plained 7.1%. In the IG, the preferred model explained 
26.1% of the total variance of ΔDep t 1 t 0 , and a model with-
out gender explained 3.9%, showing that gender ex-
plained a large part of the variance in pre-post GDS 
change in the IG but not in the CG. For ΔDep t 2 t 1 , the mod-
el explained 28.9% of the variance for the CG and 23.3% 
for the IG (without gender: 29.7 and 24.7%, respectively), 
indicating that gender did not add to explaining variance 
in the follow-up period.
 Discussion 
 LCSM of the longitudinal CORDIAL data set revealed 
that the best-fitting model was a decrease in depressive 
symptoms in the IG relative to the CG. Going beyond 
previous GLM-based analyses  [18] , the current analysis 
involved 4 assessment points, covering a period of 1 year 
and 3 months. Given the progressing character of AD, 
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this is an exceptionally long time window for therapy ef-
fects seldom reported in previous research.
 The reduction in depressive symptoms was only ob-
served in female patients in the IG. This finding is in ac-
cordance with previous studies reporting women to ben-
efit more from CB therapy and supportive therapy  [33] . 
However, these findings were not unequivocal  [20, 34] . 
Clearly, further research is needed to investigate whether 
these gender differences would also apply to patients 
with AD. In the CORDIAL study, the gender effect is un-
likely to result of differences in age or baseline levels of 
depressiveness, since these variables were statistically 
controlled for. Age was included as a control variable in 
post hoc analyses, which did not change the results. Pos-
sible explanations, as also discussed in the original pub-
lication  [18] , might be that specific parts of the therapy 
might be better suited to female patients. Alternatively, 
the benefit to male patients from the CB/CR intervention 
might have been smaller because their caregivers – pre-
ponderantly women, mostly their wives – might, even 
prior to therapy, have been more active e.g. in initiating 
social activities or ensuring a day structure based on their 
lifetime experience in family management. As a conse-
quence, the subjectively perceived difference induced by 
the CB/CR intervention might have been smaller, result-
ing in more moderate differences in the GDS self-report 
measure. An additional depression scale filled in by the 
independent observers might have been valuable in this 
context.
 As a second influencing factor, the baseline level of 
depression considerably influenced the degree of symp-
tom reduction. This influence was independent of the 
group, but the total reduction in symptoms was gener-
ally smaller in the CG. It should be mentioned in this 
context that the presence of early AD, and not depres-
sion, was the inclusion criterion for the CORDIAL sam-
ple, resulting in a large variability of depressive symp-
toms. LCSM revealed that with every additional point 
above average on the GDS at baseline, the number of de-
pressive symptoms was reduced by 0.33 GDS points at t 1 
in addition to the intercept reduction of 0.81 GDS points 
for an averagely depressed patient of either group. Com-
bining the effects of the intervention and gender in the 
model for clinically depressed patients showed an un-
doubtedly clinically relevant reduction of 5.5 points on 
the GDS scale for an average female AD patient with a 
GDS score above the cutoff ( fig. 2 ). As a possible limita-
tion, the number of variables analyzed in our model was 
restricted due to the sample size. Further studies on this 
topic could, if involving larger samples or several mea-
sures per construct, incorporate factors that might fur-
ther elucidate the intervention and gender effect found 
here. 
 In summary, the reported analyses may expand our 
knowledge about evaluation methods in two main re-
spects. First, regarding clinical studies in general, our 
study may exemplarily show that LCSM is well suited to 
modeling data from clinical studies, especially those 
with high variability within groups, as is typical for the 
aged and for patients with age-associated cognitive dis-
orders. In the future, modeling approaches such as 
LCSM may be extended to other research questions re-
lated to differential indication in the aged or in other 
subpopulations. For heart disease, there is evidence for 
a gender-specific efficacy of diagnosis and treatment 
 [35] . Also, treatment effects may depend on prior inter-
ventions  [36] , or even be harmful for patients with cer-
tain cotherapies  [37] . 
 Second, our study may serve as an example for future 
practical applications of LCSM, as this method can pro-
vide concrete quantitative information about the effect of 
a given intervention on patients with specific features. As 
outlined above, an average reduction on the GDS scale 
can be forecast by the model, not only for the entire group 
but also for subgroups according to gender, IG, and base-
line depressive symptoms. Concededly, this approach 
may enhance the complexity of diagnostics and treatment 
decisions, and translating this knowledge into daily clini-
cal routines may still be challenging. Nevertheless, in ac-
cordance with the vision of individualized medicine in 
the 21st century, LCSM may represent a tool for tailoring 
interventions to patients in a truly evidence-based man-
ner. 
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